Tag Archive for: Clinical Trial

Synendos Therapeutics AG Granted EMA Clinical Trial Authorisation for first-in-class Endocannabinoid System modulator, SYT-510

/in

Synendos Therapeutics transitions to a clinical-stage biotech company developing innovative Endocannabinoid System (ECS) treatments for neuropsychiatric, neuroinflammatory and other Central Nervous System (CNS) disorders Clinical Trial will investigate the safety, tolerability and pharmacokinetics of Synendos’ first-in-class ECS modulator BASEL, Switzerland – 18 January 2024 – Synendos Therapeutics AG (Synendos), a world leader in innovative Endocannabinoid System […]

Read more

Amber Implants Announces Start of Clinical Trial with VCFix® Spinal System

/in

Pioneering Safer and More Effective Solutions for Vertebral Fractures The Hague, Netherlands, 3 October 2023: Amber Implants, an innovative medical technology company developing next-generation implants for spinal injuries, today announces the official start of the clinical trial for the VCFix® Spinal System. Read more…

Read more

Rejuvenate Biomed announces publication of data showing that RJx-01 significantly increases muscle mass, muscle strength and physical performance in sarcopenia mouse models

/in

Sarcopenia – age-related loss of muscle mass and strength – affects up to 1 in 5 elderly people globallyi but there are no approved drugs The newly-published data validate the predictive value of Rejuvenate Biomed’s proprietary drug discovery platforms and have accelerated the advancement of RJx-01 into an ongoing 6-week placebo-controlled trial in human volunteers Diepenbeek, […]

Read more

Acesion Pharma Announces Positive Pre-Clinical Data for AP31969

/in

Copenhagen, Denmark – Acesion Pharma (“Acesion” or “the Company”), a biotech company pioneering first-in-class novel therapies for atrial fibrillation (“AF”), the most common cardiac arrhythmia, today announces positive data from pre-clinical studies with AP31969, its second-generation oral SK channel inhibitor developed for chronic oral maintenance treatment to prevent AF recurrence. Acesion aims to develop a […]

Read more

Vicore initiates clinical proof-of-concept study of endothelial dysfunction

/in

Stockholm, May 3, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), today announces the first patient dosed with C21 in a clinical study of endothelial dysfunction. Endothelial dysfunction is a key driver of organ damage associated with […]

Read more
© Optimum Strategic Communications.